Skip to main content
EyeGene,Inc logo

EyeGene,Inc — Investor Relations & Filings

Ticker · 185490 ISIN · KR7185490000 KO Professional, scientific and technical activities
Open in API
Filings indexed 314 across all filing types
Latest filing 2022-11-18 Regulatory Filings
Country KR South Korea
Listing KO 185490

About EyeGene,Inc

https://eyegene.co.kr/en/

EyeGene, Inc. is a clinical-stage biopharmaceutical company that researches and develops innovative therapeutics, with a primary focus on gene and cell therapy for age-related diseases. The company's pipeline includes EG-Mirotin, a treatment candidate for non-proliferative diabetic retinopathy and dry age-related macular degeneration. EyeGene is also developing preventive vaccines, such as EG-HPV for cervical cancer, utilizing its proprietary EG-Vac adjuvant system to enhance vaccine efficacy. The company is dedicated to creating transformative treatments by advancing biomedical science.

Recent filings

Filing Released Lang Actions
[기재정정]기타경영사항(자율공시)([국책과제 선정] 코로나19 치료제.백신 개발 - 코로나 19 백신 임상 지원 종료 정산)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Eutilex/Eyegene) titled 'Other Management Matters (Voluntary Disclosure)'. It details a correction to a previous disclosure regarding a government-funded research project (COVID-19 vaccine development). Since it is a voluntary disclosure of a specific corporate event (project settlement/correction) and does not fit into specific categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2022-11-18 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '아이진 주식회사' (EyeGene Inc.) covering the period from 2022-01-01 to 2022-09-30. It contains detailed corporate information, management discussion, business operations, and financial structure, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in collateralized shares, and the purpose of holding (influence on management) by the major shareholder and special related parties. This corresponds to the 'Major Shareholding Notification' category.
2022-10-19 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Correction Report) regarding previously granted stock options. It details changes to the list of recipients and the number of shares granted. Since this relates to the company's capital structure and equity-based compensation, and does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for new capital issuance), it falls under the general regulatory filing category for corporate announcements regarding equity incentives.
2022-09-06 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to employees and executives, including the number of shares, exercise price, and board approval details. This type of disclosure regarding capital structure changes and equity-based compensation is classified as a regulatory filing under the RNS category, as it does not fit into specific categories like DIRS (which is for personal insider trades) or SHA (which is for general share issues/capital changes).
2022-09-06 Korean
투자판단관련주요경영사항(mRNA 기반 코로나-19 예방백신 (EG-COVID) 남아프리카공화국 부스터 임상 제 1/2a상 시험 계획 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KRX) system (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the approval of a Phase 1/2a clinical trial for a COVID-19 vaccine in South Africa. Since this is a specific regulatory disclosure regarding clinical trial progress and does not fit into categories like financial reports, dividends, or board changes, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2022-09-01 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.